<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101127833</journal-id>
<journal-id journal-id-type="pubmed-jr-id">27020</journal-id>
<journal-id journal-id-type="nlm-ta">Expert Opin Ther Targets</journal-id>
<journal-id journal-id-type="iso-abbrev">Expert Opin. Ther. Targets</journal-id>
<journal-title-group>
<journal-title>Expert opinion on therapeutic targets</journal-title>
</journal-title-group>
<issn pub-type="ppub">1472-8222</issn>
<issn pub-type="epub">1744-7631</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26558806</article-id>
<article-id pub-id-type="pmc">4902328</article-id>
<article-id pub-id-type="doi">10.1517/14728222.2016.1115837</article-id>
<article-id pub-id-type="manuscript">NIHMS792344</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Potential therapeutic approaches for Angelman syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Bi</surname>
<given-names>Xiaoning</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sun</surname>
<given-names>Jiandong</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ji</surname>
<given-names>Angela X.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baudry</surname>
<given-names>Michel</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Basic Medical Sciences, COMP, Western University of Health Sciences, 701 E. Second Street, Pomona, CA 91766, USA</aff>
<aff id="A2"><label>2</label>Graduate College of Biomedical Sciences, Western University of Health Sciences, 701 E. Second Street, Pomona, CA 91766, USA</aff>
<pub-date pub-type="nihms-submitted">
<day>7</day>
<month>6</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>26</day>
<month>11</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="ppub">
<month>5</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>11</month>
<year>2016</year>
</pub-date>
<volume>20</volume>
<issue>5</issue>
<fpage>601</fpage>
<lpage>613</lpage>
<!--elocation-id from pubmed: 10.1517/14728222.2016.1115837-->
<abstract>
<sec id="S1">
<title>INTRODUCTION</title>
<p id="P1">Angelman syndrome (AS) is a neurodevelopmental disorder caused by deficiency of maternally inherited UBE3A, an ubiquitin E3 ligase. Despite recent progress in understanding the mechanism underlying <italic>UBE3A</italic> imprinting, there is no effective treatment. Further investigation of the roles played by UBE3A in the central nervous system (CNS) is needed for developing effective therapies.</p>
</sec>
<sec id="S2">
<title>AREA COVERED</title>
<p id="P2">This review covers the literature related to genetic classifications of AS, recent discoveries regarding the regulation of <italic>UBE3A</italic> imprinting, alterations in cell signaling in various brain regions, and potential therapeutic approaches. Since a large proportion of AS patients exhibit comorbid autism spectrum disorder (ASD), potential common molecular bases are discussed.</p>
</sec>
<sec id="S3">
<title>EXPERT OPINION</title>
<p id="P3">Advances in understanding <italic>UBE3A</italic> imprinting provide a unique opportunity to induce paternal <italic>UBE3A</italic> expression, thus targeting the syndrome at its “root.” However, such efforts have yielded less-than-expected rescue effects in AS mouse models, raising the concern that activation of paternal UBE3A after a critical period cannot correct all the CNS defects that developed in a UBE3A-deficient environment. On the other hand, targeting abnormal downstream cell signaling pathways has provided promising rescue effects in preclinical research. Thus, combined reinstatement of paternal <italic>UBE3A</italic> expression with targeting abnormal signaling pathways should provide better therapeutic effects.</p>
</sec>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>